Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A CD21 low phenotype, with no evidence of autoantibodies to complement proteins, is consistent with a poor prognosis in CLL.

Oncotarget - 20 Oct 2015

Nichols Eva-Maria, Jones Rachel, Watson Rachael, Pepper Chris J, Fegan Chris, Marchbank Kevin J

Abstract excerpt

B-cell chronic lymphocytic leukemia (CLL) is characterized by differential BCR signaling and autoimmune complications. Complement modulates B-cell function via C3d and CD21 cross-linked to the B-cell receptor (BCR). We hypothesized that CD21 contributes to BCR signaling and participates in the autoimmunity associated with CLL. We analyzed CD21 expression on 106 CLL patient samples and matched serum from 50...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to ADP-ribosyl Cyclase 1
Share to CD79 Antigens

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Complement System Proteins

Share to Genes, Immunoglobulin Heavy Chain

Share to Phosphotyrosine

Share to Receptors, Antigen, B-Cell

Share to Receptors, Complement 3d

Share to ZAP-70 Protein-Tyrosine Kinase

Source

Open in PubMed Open full text

Identifiers

PMID: 26452134
DOI: 10.18632/oncotarget.5404
PMCID: PMC4741721

Genes

BCR
ZAP70

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A CD21 low phenotype, with no evidence of autoantibodies to complement proteins, is consistent with a poor prognosis in CLL.PMID 26452134Read ↗

B cell activation leads to shedding of complement receptor type II (CR2/CD21)Semantic proximity Read ↗

Circulating CD21low B cells in common variable immunodeficiency resemble tissue homing, innate-like B cells.Semantic proximity Read ↗

Phenotypic analysis of receptor-ligand pairs on B-cells in B-chronic lymphocytic leukemia.Semantic proximity Read ↗

Deep Phenotyping of CD11c+ B Cells in Systemic Autoimmunity and Controls.Semantic proximity Read ↗

Expansion of functionally anergic CD21-/low marginal zone-like B cell clones in hepatitis C virus infection-related autoimmunity.Semantic proximity Read ↗

Human complement receptor type 1/CD35 is an Epstein-Barr Virus receptor.Semantic proximity Read ↗

CD21 and CD19 deficiency: Two defects in the same complex leading to different disease modalities.Semantic proximity Read ↗

Accumulation of Antigen-Driven Lymphoproliferations in Complement Receptor 2/CD21-/low B Cells From Patients With Sjögren's Syndrome.Semantic proximity Read ↗

The crystal structure of human CD21: Implications for Epstein–Barr virus and C3d bindingSemantic proximity Read ↗

Elevated Numbers of Immature/Transitional CD21− B Lymphocytes and Deficiency of Memory CD27+ B Cells Identify Patients with Active Chronic Graft-versus-Host DiseaseSemantic proximity Read ↗

Targeting the Immune Complex–Bound Complement C3d Ligand as a Novel Therapy for LupusSemantic proximity Read ↗

Structural requirements for C3d,g/Epstein-Barr virus receptor (CR2/CD21) ligand binding, internalization, and viral infection.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.